May 04, 2017
Sponsored by
Qiagen

Liquid Biopsies for Improved Recurrence Monitoring in Colorectal Cancer

GenomeWebinar

CEO, Director & Co-Founder,
Clinical Genomics

Associate Director, New Product Quality Assurance,
Qiagen

This online seminar will provide an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.

Analysis of circulating tumor DNA (ctDNA) has the potential to improve detection and monitoring of cancers in order to significantly impact patient outcomes. This is especially important for cancers with a high rate of recurrence, such as colorectal cancer, where between 30 percent and 40 percent of cases recur. However, the only currently available monitoring blood test misses 74 percent of resectable recurrences.

In this webinar, Dr. Lawrence LaPointe, CEO of Clinical Genomics, will discuss how his team is working with Qiagen to develop a ctDNA test for colorectal cancer recurrence monitoring.

Additionally, Dr. Martin Horlitz will briefly share how Qiagen's ctDNA extraction chemistries are compliant with ISO and IVD quality guidelines.

Sponsored by

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.

May
04
Sponsored by
Qiagen

This online seminar will provide an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.

May
11
Sponsored by
PerkinElmer

This webinar will provide an overview of an RNA-seq protocol that has been optimized to study small RNA species such as microRNAs.

May
23
Sponsored by
Agilent Technologies

This webinar will discuss a target enrichment workflow for high-confidence detection of variants. 

Jun
20
Sponsored by
OmniSeq

This webinar will discuss RNA sequencing as an alternative to immunohistochemistry (IHC) in selecting patients for cancer immunotherapy.